CDC opts for £370 million buy-in deal with Goldman subsidiary

Concern over the long-term viability of financial institutions led UK government-owned emerging market investment vehicle the CDC Group to opt for a fully collateralised buy-in when offloading its pension liabilities in a £370 million deal with Goldman Sachs’ offshoot Rothesay Life.

According to John Deed, a trustee of the CDC Group’s pension scheme, uncertainty over the global economy made the issue of securing a collateral-based deal all the more pressing: “We moved from a situation where

To continue reading...

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: